Positron emission tomography scanning for malignant melanoma and positive sentinel node diagnostics;PET-skanning ved malignt melanom og positiv sentinel node

Ugeskrift for Laeger

Volumn 172, Issue 15, 2010, Pages

  Horn, Janne ^a   Sjøstrand, Helle ^a   Lock Andersen, Jørgen ^a  

^a University of Copenhagen   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MALE; MELANOMA; METASTASIS; MIDDLE AGED; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; RETROSPECTIVE STUDY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; SKIN TUMOR;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS;

EID: 77951930138     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Sundhedsstyrelsen: Cancerregisteret 2007.www.sst.dk
2. Balch cm, Soong S, Gershenwald JE et al. Prognostic factors analysis of 17,6000 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622-34.
3. Wagner JD, Schauwecker DS, Davidson et al. FDG-PET sensitivity for melanoma lymph node metastasis is dependent on tumour volume. J Surg Oncol 2001;77:237-242.
4. Horn J, Lock-Andersen J, Sjøstrand H et al. Routine use of FDG-PET scans in -melanoma patients with positive sentinel node biopsy. Eur J Nucl Med Mol -Imaging 2006;33[8]:887-892.
5. Lock-Andersen J, Horn J, Sjøstrand H et al. Sentinel node biopsy in cutaneous melanoma. Scand J Plast Reconstr Hand Surg 2006;40[1]:24-31.
6. Lock-Andersn J, Horn J, Sjøstrand H. Prognosen efter sentinel node biopsy ved malignt melanom. Ugeskr Læger 2006; 168[25]: 2457-62.
7. Dansk Melanom Gruppes protokol : www.melanoma.dk
8. Constantinidou A, Hofman M, O'Doherty M et al. Routine positron emission -tomography and positron emission tomography/computed tomography in -melanoma staging with positive sentinel node biopsy is of limited benefit. Mel Res 2008;18:56-60.
9. Eigtved A, Andersson, Dahlstrøm K et al. Use of flourine-18 flourodeoxyglukose positron emission tomography in the detection of silent metastases from -malignant melanoma. Eur J Nucl Med 2000;27:70-75.
10. Longo MI, Lazaro P, Bueno C et al. Flourodeoxyglukose-positron emission -tomography imaging versus sentinel node biopsy in the primary staging of -melanoma patients. Dermatol Surg 2003;29:245-48.
11. Swetter S, Caroll L, Johnson D et al. Positron emission tomography (PET) is -superior to computerized tomography(CT) for metastatic staging in melanoma patients. Clin Positron Imaging 2000;3:154.
12. Fuster D, Chiang S, Johnson G et al. Is 18 FDG more accurate than standard diagnostic procedures in the detection of suspected recurrent melanoma? J Nucl Med 2004;45:1323-27.